StockData
Sionna Therapeutics, Inc. logo

Sionna Therapeutics, Inc. (SION) company profile

SIONNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 7/30
$3.07−0.05 (-1.60%)

Close on Nov 17, 2026Market cap $138.80MP/E –Yield –

About Sionna Therapeutics

Pharmaceutical Preparations, SIC 2834

This clinical-stage biopharmaceutical company discovers and develops small-molecule therapeutics to treat cystic fibrosis by restoring CFTR protein function. Its pipeline centers on nucleotide binding domain 1 (NBD1) stabilizers, notably lead candidates SION-719 and SION-451, designed to correct defects caused by the F508del genetic mutation. The company also advances complementary CFTR modulators, including transmembrane domain 1 correctors such as SION-2222 and SION-2851, the intracellular loop 4 corrector SION-109, and the potentiator SION-3067. Its product candidates are designed either to be administered alongside the existing standard of care or paired into proprietary dual-combination therapies. The company targets people living with cystic fibrosis, particularly individuals carrying the F508del mutation.

The company operates as a clinical-stage entity without disclosing commercial offices, physical facilities, or operational territories in the excerpt. Its clinical development activities encompass Phase 1 and Phase 2a clinical trials evaluating healthy adult participants and cystic fibrosis patients. The provided text does not state the location of the company's headquarters.

Summary of the business section of Sionna Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
Sionna Therapeutics, Inc.
Headquarters
Waltham, MA
Address
21 Hickory Drive, Suite 500 02451
Phone
(617) 819-2020
Employees
59, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Deloitte& Touche LLP, Boston, Massachusetts

Stock & identifiers

Ticker
SION
Exchange
Nasdaq
IPO date
Feb 7, 2025
Shares outstanding
45M, Jul 31, 2026
Public float
$342.01M, Jun 30, 2025
Filer category
<br>Emerging growth company
SEC CIK
2036042
CUSIP
829401108
ISIN
US8294011080
FIGI
BBG016X2DC85
Share class FIGI
BBG016X2DCF7
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Michael CloonanPresident & CEO, Director765,393
Charlotte McKeeCMO and Head of R&D78,415
Elena RidloffCFO and CBO85,801
Jennifer FitzpatrickCLO and Head of Program Mgmt.28,133
Caroline Stark BeerChief Business Officer–
Ra Capital Management, L.P.Director3,448,812
Capital Healthcare Fund LP RADirector–
Rajeev M. ShahDirector–
RA Capital Nexus Fund III, L.P.Director715,988
Peter KolchinskyDirector2,198,082
RA Capital Nexus Fund, L.P.Director–
Capital GP VIII LLC OrbiMedDirector2,469,959
Peter A. ThompsonDirector2,469,959
Advisors Llc OrbimedDirector2,555,877
Harold Edward FlemingDirector–
Joanne L. VineyDirector–
Marcella K. RuddyDirector–
Paul J. ClancyDirector–
Bruce BoothDirector3,057,453
Laurie StelzerDirector–
Joshua ResnickDirector–
Lucian IancoviciDirector–

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusOption awardsIncentive payOtherTotalvs. prior year
Michael Cloonan
President and Chief Executive Officer
$646.58K–$5.95M$374.06K$10.00K$6.98M+87%
Elena Ridloff
Chief Financial Officer
$506.68K–$2.09M$254.93K$10.00K$2.86M+120%
Caroline Stark Beer
Chief Business Officer
$158.95K$30.00K$5.32M$71.60K$7.57K$5.59M–

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Feb 7, 2025
Offer price
$18.00
Securities offered
10,588,233
Gross proceeds
$190.59M
Exchange
Nasdaq
First trading day
Feb 7, 2025
First-day close
$25.00+38.9%
Lock-up ends (est.)
Aug 6, 2025

“The initial public offering price per share is $18.00.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of February 15, 2026, we had 59 full-time employees, of which 15 had M.D.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?